ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-PO1120

Limited Antiproteinuric Efficacy of Dapagliflozin (DPG) in Adolescents with Proteinuric CKD

Session Information

  • Late-Breaking Posters
    November 02, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Pediatric Nephrology

  • 1900 Pediatric Nephrology


  • Ramakrishna, Swathi, All India Institute of Medical Sciences, New Delhi, Delhi, India
  • Sinha, Aditi, All India Institute of Medical Sciences, New Delhi, Delhi, India
  • Bagga, Arvind, All India Institute of Medical Sciences, New Delhi, Delhi, India

While reducing proteinuria is renoprotective in CKD, it might persist despite renin-angiotensin-aldosterone (RAAS) blockade. SGLT2 inhibitors, known to be antiproteinuric in adult-onset CKD, have not been tested in children.


This single-center trial examined the antiproteinuric efficacy & safety of DPG in adolescents with CKD (CTRI/2022/04/042032). After written consent & baseline evaluation, consecutive eligible patients, 11-19 yr old with eGFR >45 ml/min/1.73 m2 & proteinuria >0.5 g/m2/d despite optimal RAAS blockade, received Dapavel® at 5 mg/d x 2-wk, followed by 10 mg/d x 10-wk. Biochemistry & 24-hr urine protein/albumin were repeated at 4, 8 & 12-wk, and ambulatory blood pressure at 12-wk.


Of 49 screened, 25 patients (76% boys, chiefly glomerular CKD), were enrolled at median eGFR 93 ml/min/1.73 m2 & proteinuria 1.4 g/m2/d (Table 1). Fig. 1 shows outcomes at 4 & 12-wk. At 12-wk, proteinuria declined by median 1.3% and eGFR by 13.4%; 4 (16%) patients achieved the FSGS proteinuria reduction endpoint. 3 patients noted giddiness; none had serious adverse events.


Therapy with DPG for 12-wk has limited antiproteinuric efficacy in adolescents with CKD. Controlled studies should examine the antiproteinuric effect and optimal dose & duration of SGLT2 inhibitors in children.

Fig. 1. Outcomes at 4- and 12-wk, as median (interquartile range).